From our survey
Is it legal, will I be high, can I drive home, does MO HealthNet end the conversation: direct answers with their limits attached.
These are the questions people ask when they are not trying to be polite. No preamble, no inspirational opening, just answers with their limits attached.
First, know that being unsure puts you in the majority. Our commissioned poll drew 443 adults from ten Midwest states, and their reactions to ketamine or esketamine therapy split like this: negative 9 percent, skeptical 21, cautious but open 34, hopeful or curious 18, and never heard of it 18. The figures have passed the panel's final validation.
Yes. Ketamine is a controlled substance with long medical use, and esketamine, the drug in Spravato, has FDA approval for treatment-resistant depression. The interesting question is oversight, not legality. The approved spray is used in a certified clinic with monitoring; clinic infusions of generic ketamine are off label; a prescription mailed to you after a video call has the least supervision of all.
You may feel dissociated: floating, distant from your body, or as if time has stretched. That is an expected effect, not a complication, and it is why the approved product is used where someone can watch you. Some people find it interesting and some find it deeply unpleasant. Both are normal, and neither predicts whether the treatment helps.
Longer than the dose, since you stay to be observed.
No. With the approved treatment someone else drives, and you stay off the road for the rest of the day. Solve that before booking, because it is what most often breaks the plan in week two. Our respondents felt it too: 43 percent wanted a clinic near home as one of their two chief criteria, second only to insurance at 85 percent.
Ketamine has recognized misuse potential, which is exactly why the approved product is confined to certified settings and never handed over as a bottle to keep. It argues for the most supervised version available rather than the most convenient. Whether your own history raises the concern is a question for a clinician.
We have no pricing data and will not invent a range. To get a real number, request a benefits determination in writing, using your own plan and member number, before the first appointment, and ask what you owe if the claim is denied later.
Our respondents treated money as the deciding variable. Coverage was make-or-break, or nearly, for 65 percent. Given the choice, 51 percent would accept a slower insured path over a quicker self-paid one; the rest split 23 percent for paying and 26 percent unsure.
It should not, and the payer mix in this survey is why. Medicaid was reported by 37 percent of respondents, nearly level with commercial insurance at 39; Medicare stood at 23, while the uninsured and TRICARE accounted for 9 and 5. That is a mainstream share, and a clinic that treats Medicaid as an afterthought is telling you who it built its business for. Ask if it is enrolled, and whether it has ever actually been paid.
Do not stop any medication because an article or a clinic implied you should. The approved esketamine treatment is used together with an oral antidepressant, not in place of one, and any change is a decision for the prescriber who knows your history.
Then it does not, and a serious program tells you in advance how and when that call gets made. Ask for the criteria before you start. A clinic with no stopping point has a subscription, not a plan.
Probably because it almost never comes up. In our results, the brand was a stranger to 73 percent of respondents; 21 percent had brushed past the name, and 6 percent could explain it. The awareness gap runs through the whole population.
So ask rather than wait. Most people plan to begin there anyway: 56 percent of respondents would start with the primary doctor; 23 percent would begin with a psychiatrist or therapist and 12 percent with a web search, while a few (5 percent) had no idea and fewer still (1 percent) would ask a friend.
The sample was emphatic. For 74 percent, what would tip them toward trying it is their own doctor saying so. Friends and family trailed at 18 percent; a service member or first responder with an online following moved 4 percent, ads moved 2, and podcasters 1.
When 2 percent trust advertising, the only opinion worth buying comes from someone who has read your chart.
Make it answer four things plainly: which product it provides, who is licensed and physically present during a session, what your plan covers in writing, and how it will coordinate with your current prescriber. Vagueness on any of the four is an answer. If you want a sense of what clear answers sound like, Brain Recovery Centers publishes a plain description of its Spravato treatment.
That is not ours to say. What the data shows is that plenty of people stand where you do. Among our respondents, 72 percent had watched depression, anxiety, or PTSD outlast standard medication, in themselves or someone close: 37 percent personally and 22 percent via someone close, 13 percent both ways, leaving 28 percent untouched. Widespread need is not evidence that a treatment fits you. Only a clinical evaluation gets you there, and nothing here is medical advice.
One answer does not wait for an evaluation. If ending your life has crossed your mind, call or text 988 and a Lifeline counselor picks up, any hour, free. It is there for bad nights as well as emergencies, and you owe no one an explanation for reaching out.
Every percentage here comes from one commissioned study, Pollfish consumer panel survey 395586438, which this publisher funded. Respondents, n=443, were ordinary members of the public, 18 to 64, from ten Midwest states, not patients; fieldwork ended June 23, 2026. Questions allowing several answers are reported as shares of respondents and pass 100. The panel provider has completed validation of these data. Only top-line results appear, so no figure represents a subgroup.